Shares of cell programming platform company Ginkgo Bioworks Holdings Inc DNA are moving lower after hours on the heels of a wider-than-expected quarterly loss.
- Q1 Revenue: $80.7 million beat estimates of $71.68 million
- Q1 EPS: Loss of 11 cents missed estimates for loss of 9 cents
Ginkgo ended the quarter with approximately $1.2 billion in cash and equivalents, which is expected to provide the company with a "multi-year runway and a margin of safety in an otherwise challenging market environment."
Ginkgo said it added 13 new cell programs in the first quarter, up 18% year-over-year.
"There is no doubt that we are going to be living in a challenging market environment for a while, but Ginkgo was built for these moments — we have worked hard to give ourselves a margin of safety so that we can relentlessly focus on our mission to make biology easier to engineer," said Jason Kelly, co-founder and CEO of Ginkgo.
FY23 Outlook: Ginkgo continues to expect to add 100 new cell programs to its platform this year. Full-year revenue is expected to be at least $275 million.
See Also: Why Unity Software Stock Is Rising After Hours
DNA Price Action: Ginkgo Bioworks shares were down 8.89% after the bell at $1.23 at the time of publication, per Benzinga Pro.
Photo: Arek Socha from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.